Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Yang JC, et al. Among authors: hirsh v. J Clin Oncol. 2013 Sep 20;31(27):3342-50. doi: 10.1200/JCO.2012.46.1764. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816967 Clinical Trial.
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.
von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. von Pawel J, et al. Among authors: hirsh v. J Clin Oncol. 2000 Mar;18(6):1351-9. doi: 10.1200/JCO.2000.18.6.1351. J Clin Oncol. 2000. PMID: 10715308 Clinical Trial.
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Shepherd FA, et al. Among authors: hirsh v. J Clin Oncol. 2002 Nov 15;20(22):4434-9. doi: 10.1200/JCO.2002.02.108. J Clin Oncol. 2002. PMID: 12431965 Clinical Trial.
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gridelli C, et al. Among authors: hirsh v. J Clin Oncol. 2003 Aug 15;21(16):3025-34. doi: 10.1200/JCO.2003.06.099. Epub 2003 Jul 1. J Clin Oncol. 2003. PMID: 12837810 Clinical Trial.
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Rosen LS, et al. Among authors: hirsh v. J Clin Oncol. 2003 Aug 15;21(16):3150-7. doi: 10.1200/JCO.2003.04.105. J Clin Oncol. 2003. PMID: 12915606 Clinical Trial.
Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial.
Hirsh V, Latreille J, Kreisman H, Desjardins P, Ofiara L, Whittom R, Fox S, Palayew MD, Pintos J. Hirsh V, et al. Lung Cancer. 2005 Jul;49(1):117-23. doi: 10.1016/j.lungcan.2004.11.029. Epub 2005 Feb 16. Lung Cancer. 2005. PMID: 15949597 Clinical Trial.
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L. Hirsh V, et al. J Thorac Oncol. 2007 Oct;2(10):927-32. doi: 10.1097/JTO.0b013e3181560b92. J Thorac Oncol. 2007. PMID: 17909355 Free article. Clinical Trial.
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Manegold C, et al. Among authors: hirsh v. J Clin Oncol. 2008 Aug 20;26(24):3979-86. doi: 10.1200/JCO.2007.12.5807. J Clin Oncol. 2008. PMID: 18711188 Clinical Trial.
131 results